These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 24148817

  • 21. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
    Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E.
    Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
    [Abstract] [Full Text] [Related]

  • 22. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [Abstract] [Full Text] [Related]

  • 23. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B.
    PLoS One; 2013 Sep; 8(3):e57346. PubMed ID: 23483902
    [Abstract] [Full Text] [Related]

  • 24. Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.
    Birnie KA, Yip YY, Ng DC, Kirschner MB, Reid G, Prêle CM, Musk AW, Lee YC, Thompson PJ, Mutsaers SE, Badrian B.
    Mol Cancer Res; 2015 Jul; 13(7):1106-18. PubMed ID: 25824152
    [Abstract] [Full Text] [Related]

  • 25. 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
    De A, Jacobson BA, Peterson MS, Jay-Dixon J, Kratzke MG, Sadiq AA, Patel MR, Kratzke RA.
    Invest New Drugs; 2018 Apr; 36(2):217-229. PubMed ID: 29116477
    [Abstract] [Full Text] [Related]

  • 26. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
    Manente AG, Pinton G, Zonca S, Cilli M, Rinaldi M, Daga A, Nilsson S, Moro L.
    Oncotarget; 2015 Sep 22; 6(28):25121-34. PubMed ID: 26208479
    [Abstract] [Full Text] [Related]

  • 27. Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment.
    Karatkevich D, Losmanova T, Zens P, Deng H, Dubey C, Zhang T, Casty C, Gao Y, Neppl C, Berezowska S, Wang W, Peng RW, Schmid RA, Dorn P, Marti TM.
    Sci Rep; 2024 Aug 06; 14(1):18206. PubMed ID: 39107509
    [Abstract] [Full Text] [Related]

  • 28. Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.
    Cioce M, Canino C, Pulito C, Muti P, Strano S, Blandino G.
    Cell Cycle; 2012 Jan 01; 11(1):132-40. PubMed ID: 22185775
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
    Meerang M, Bérard K, Felley-Bosco E, Lauk O, Vrugt B, Boss A, Kenkel D, Broggini-Tenzer A, Stahel RA, Arni S, Weder W, Opitz I.
    Mol Cancer Ther; 2016 May 01; 15(5):1095-105. PubMed ID: 26839306
    [Abstract] [Full Text] [Related]

  • 33. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld J, Iorio F, Kolluri K, Garnett M, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C.
    Clin Cancer Res; 2018 Jan 01; 24(1):84-94. PubMed ID: 29061644
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
    Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D'Incalci M, Frapolli R.
    Int J Cancer; 2017 Jan 01; 140(1):197-207. PubMed ID: 27594045
    [Abstract] [Full Text] [Related]

  • 36. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.
    Tucker TA, Dean C, Komissarov AA, Koenig K, Mazar AP, Pendurthi U, Allen T, Idell S.
    Am J Respir Cell Mol Biol; 2010 Jun 01; 42(6):685-96. PubMed ID: 19635932
    [Abstract] [Full Text] [Related]

  • 37. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
    Volta V, Ranzato E, Martinotti S, Gallo S, Russo MV, Mutti L, Biffo S, Burlando B.
    PLoS One; 2013 Jun 01; 8(3):e58051. PubMed ID: 23526965
    [Abstract] [Full Text] [Related]

  • 38. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
    Ueno T, Toyooka S, Fukazawa T, Kubo T, Soh J, Asano H, Muraoka T, Tanaka N, Maki Y, Shien K, Furukawa M, Sakaguchi M, Yamamoto H, Tsukuda K, Miyoshi S.
    Acta Med Okayama; 2014 Jun 01; 68(1):23-6. PubMed ID: 24553485
    [Abstract] [Full Text] [Related]

  • 39. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
    Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K.
    Virchows Arch; 2013 Jan 01; 462(1):83-93. PubMed ID: 23187830
    [Abstract] [Full Text] [Related]

  • 40. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
    Hegedüs L, Okumus Ö, Mairinger F, Ploenes T, Reuter S, Schuler M, Welt A, Vega-Rubin-de-Celis S, Theegarten D, Bankfalvi A, Aigner C, Hegedüs B.
    Lung Cancer; 2023 Apr 01; 178():237-246. PubMed ID: 36907051
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.